Role of Acetylcysteine in Creatinine Clearance
| Status: | Unknown status |
|---|---|
| Healthy: | No |
| Age Range: | 18 - 79 |
| Updated: | 10/14/2017 |
| Start Date: | October 2006 |
| Contact: | Ritche Chiu, MD |
| Email: | dr_ritchechiu@yahoo.com |
| Phone: | 757-680-0211 |
The purpose of this study is to investigate the exact role of Acetylcysteine (Mucomyst) in
altering creatinine clearance. Prior studies have shown the protective effects of
Acetylcysteine on contrast-induced renal dysfunction. In these studies, Acetylcysteine
lowered the incidence of serum creatinine elevation after administration of radiographic
contrast agents. Not only was the increase in serum creatinine prevented, the studies also
demonstrated a significant increase in creatinine clearance after administration of the
agent. These prior studies did not evaluate if the increase in creatinine clearance was
indeed from a protective benefit of Acetylcysteine in preserving the GFR versus simply
increasing the proximal tubular creatinine secretion without actually affecting the GFR. We
propose an experiment to help support our hypothesis that Acetylcysteine increases creatinine
clearance via an increase in proximal tubular secretion of creatinine.
altering creatinine clearance. Prior studies have shown the protective effects of
Acetylcysteine on contrast-induced renal dysfunction. In these studies, Acetylcysteine
lowered the incidence of serum creatinine elevation after administration of radiographic
contrast agents. Not only was the increase in serum creatinine prevented, the studies also
demonstrated a significant increase in creatinine clearance after administration of the
agent. These prior studies did not evaluate if the increase in creatinine clearance was
indeed from a protective benefit of Acetylcysteine in preserving the GFR versus simply
increasing the proximal tubular creatinine secretion without actually affecting the GFR. We
propose an experiment to help support our hypothesis that Acetylcysteine increases creatinine
clearance via an increase in proximal tubular secretion of creatinine.
Inclusion Criteria:
1. Between the ages of 18 and 79 years
2. In good general health
3. Able to provide informed consent
Exclusion Criteria:
1. Allergy to acetylcysteine or cimetidine,
2. Age less than 18 years or greater than 79 years of age,
3. Women of childbearing age and not able to use adequate contraception, or 4. Anyone
currently on any medication that interferes with tubular secretion of creatinine such
as trimethoprim-sulfamethoxazole (Bactrim).
We found this trial at
1
site
Norfolk, Virginia 23507
Principal Investigator: Thomas R. McCune, MD
Click here to add this to my saved trials
